This Phase II study is a multicenter, randomized, double-blind, placebo controlled, escalating multiple dose study intended to determine the safety and tolerance of interleukin-10 (SCH 52000), administered subcutaneously, once daily for 28 consecutive days, to patients with mildly to moderatley active idiopathic inflammatory bowel disease (Crohn's disease or ulcerative colitis).
Showing the most recent 10 out of 563 publications